<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immunic, Inc. — News on 6ix</title>
<link>https://6ix.com/company/immunic-inc</link>
<description>Latest news and press releases for Immunic, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 10:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immunic-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583a678dffbe2df0fcc85.webp</url>
<title>Immunic, Inc.</title>
<link>https://6ix.com/company/immunic-inc</link>
</image>
<item>
<title>Immunic to Participate in Investor and Medical Conferences in May</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-investor-and-medical-conferences-in-may</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-investor-and-medical-conferences-in-may</guid>
<pubDate>Thu, 30 Apr 2026 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May:</description>
</item>
<item>
<title>Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-appoints-accomplished-biopharmaceutical-executive-michael-a-panzara-md-mph-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-appoints-accomplished-biopharmaceutical-executive-michael-a-panzara-md-mph-as-chief-medical-officer</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies –– Strong Experience in Advancing Late-Stage</description>
</item>
<item>
<title>Immunic, Inc. Announces 1-for-10 Reverse Stock Split</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-inc-announces-1-for-10-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-inc-announces-1-for-10-reverse-stock-split</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026.</description>
</item>
<item>
<title>Immunic to Participate in Scientific and Medical Conferences in April</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-scientific-and-medical-conferences-in-april</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-scientific-and-medical-conferences-in-april</guid>
<pubDate>Thu, 09 Apr 2026 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April:</description>
</item>
<item>
<title>Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies</description>
</item>
<item>
<title>Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-strengthens-its-board-of-directors-with-the-appointment-of-seasoned-biopharmaceutical-executive-jon-congleton</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-strengthens-its-board-of-directors-with-the-appointment-of-seasoned-biopharmaceutical-executive-jon-congleton</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team</description>
</item>
<item>
<title>Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-announces-grant-of-key-european-patent-protecting-relevant-dosing-regimens-for-vidofludimus-calcium</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-announces-grant-of-key-european-patent-protecting-relevant-dosing-regimens-for-vidofludimus-calcium</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –– Broad Protection</description>
</item>
<item>
<title>Immunic to Participate in Investor Conferences in March</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-to-participate-in-investor-conferences-in-march</guid>
<pubDate>Tue, 03 Mar 2026 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March:</description>
</item>
<item>
<title>Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-inc-reports-year-end-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-inc-reports-year-end-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Feb 2026 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Immunic Announces Closing of Oversubscribed Private Placement Financing</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-announces-closing-oversubscribed-private-210500023</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-announces-closing-oversubscribed-private-210500023</guid>
<pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously disclosed private placement financing.</description>
</item>
<item>
<title>Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-announces-oversubscribed-private-placement-113000290</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-announces-oversubscribed-private-placement-113000290</guid>
<pubDate>Fri, 13 Feb 2026 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement with gross proceeds of up to USD 400 million priced at the market under Nasdaq rules. The financing was led by existing investor BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMe</description>
</item>
<item>
<title>Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-present-additional-phase-2-113000869</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-present-additional-phase-2-113000869</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026, ta</description>
</item>
<item>
<title>Immunic Highlights 2025 Accomplishments and Upcoming Milestones</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-highlights-2025-accomplishments-upcoming-113000120</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-highlights-2025-accomplishments-upcoming-113000120</guid>
<pubDate>Wed, 07 Jan 2026 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 accomplishments and upcoming milestones.</description>
</item>
<item>
<title>Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-participate-8th-annual-evercore-113000244</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-participate-8th-annual-evercore-113000244</guid>
<pubDate>Wed, 26 Nov 2025 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL.</description>
</item>
<item>
<title>Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-inc-reports-third-quarter-113000323</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-inc-reports-third-quarter-113000323</guid>
<pubDate>Thu, 13 Nov 2025 11:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the three and nine months ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Immunic to Participate in Industry and Investor Conferences in November</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-participate-industry-investor-conferences-103000629</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-participate-industry-investor-conferences-103000629</guid>
<pubDate>Wed, 29 Oct 2025 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November:</description>
</item>
<item>
<title>Immunic to Participate in Scientific and Investor Conferences in October</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-participate-scientific-investor-conferences-103000800</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-participate-scientific-investor-conferences-103000800</guid>
<pubDate>Wed, 01 Oct 2025 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October:</description>
</item>
<item>
<title>Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-presented-key-vidofludimus-calcium-103000645</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-presented-key-vidofludimus-calcium-103000645</guid>
<pubDate>Thu, 25 Sep 2025 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of key data in an oral and four poster presentations, including one late-breaking poster, at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025 in Barcelona, Spain. The data highlight Immunic's ora</description>
</item>
<item>
<title>Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-receives-notice-allowance-united-103000395</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-receives-notice-allowance-united-103000395</guid>
<pubDate>Tue, 09 Sep 2025 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/529,946, entitled, "Treatment of multiple sclerosis comprising DHODH inhibitors."</description>
</item>
<item>
<title>Immunic to Participate in Investor and Scientific Conferences in September</title>
<link>https://6ix.com/company/immunic-inc/news/immunic-participate-investor-scientific-conferences-103000872</link>
<guid isPermaLink="true">https://6ix.com/company/immunic-inc/news/immunic-participate-investor-scientific-conferences-103000872</guid>
<pubDate>Thu, 04 Sep 2025 10:30:00 GMT</pubDate>
<description>Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September:</description>
</item>
</channel>
</rss>